Impact of Three Anti-TNFα Biologics on Existing and Emergent Autoimmunity in Rheumatoid Arthritis and Spondylarthropathy Patients

Objective The objective of this study was to analyze the effects of 3 anti-TNFα agents on markers of autoimmunity in rheumatoid arthritis (RA) and spondylarthropathy (SPA) patients. Methods First-time anti-TNFα biologics (infliximab, etanercept, or adalimumab) were prescribed to 156 RA and 95 SPA (5...

Full description

Saved in:
Bibliographic Details
Published in:Journal of clinical immunology 2008-09, Vol.28 (5), p.445-455
Main Authors: Bacquet-Deschryver, H., Jouen, F., Quillard, M., Ménard, J. F., Goëb, V., Lequerré, T., Mejjad, O., Daragon, A., Tron, F., Le Loët, X., Vittecoq, O.
Format: Article
Language:English
Subjects:
Biomedical and Life Sciences
Biomedicine
Immunology
Infectious Diseases
Internal Medicine
Medical Microbiology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective The objective of this study was to analyze the effects of 3 anti-TNFα agents on markers of autoimmunity in rheumatoid arthritis (RA) and spondylarthropathy (SPA) patients. Methods First-time anti-TNFα biologics (infliximab, etanercept, or adalimumab) were prescribed to 156 RA and 95 SPA (58 ankylosing spondylarthritides, 37 psoriatic arthritides). During 1–2 years of follow-up, clinical, biological [antinuclear (ANA) and anti-double-stranded (dsDNA) antibodies, rheumatoid factors (RF), and anti-cyclic citrullinated peptide (CCP) for RA], and therapeutic data were collected biannually. Results ANA appeared or ANA and anti-dsDNA titers increased significantly ( P  
ISSN:0271-9142
1573-2592
DOI:10.1007/s10875-008-9214-3